18F-Flutemetamol PET/CT for Transthyretin Amyloid Cardiomyopathy Timing Matters

We report F-18-flutemetamol PET/CT finding in an 88-year-old man with cognitive impairment and transthyretin amyloid cardiomyopathy. Early phase PET/CT images showed significantly increased myocardial uptake, but there was no myocardial uptake in delayed phase PET/CT images. A dual-time-point amyloid PET/CT imaging may be helpful to diagnose and differentiate subtypes of amyloid cardiomyopathy in patients with suspected cardiac amyloidosis.

Automated summary

This report presents the use of F-18-flutemetamol PET/CT imaging findings in a case of an 88-year-old man with cognitive impairment and transthyretin amyloid cardiomyopathy. The early phase PET/CT images showed a significant increase in myocardial uptake, while the delayed phase PET/CT images did not show any myocardial uptake. Dual-time-point amyloid PET/CT imaging may be beneficial in diagnosing and distinguishing subtypes of amyloid cardiomyopathy in patients with suspected cardiac amyloidosis.